60 results
8-K
EX-99.1
ATRA
Atara Biotherapeutics Inc
28 Mar 24
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
8:35am
development process and the uncertainty of clinical success; the COVID-19 pandemic and the wars in Ukraine and the Middle East, which may
424B5
ATRA
Atara Biotherapeutics Inc
9 Jan 24
Prospectus supplement for primary offering
4:28pm
be adversely affected in the future by the effects of health epidemics and pandemics, such as the COVID-19 pandemic, which could materially and adversely
8-K
EX-99.2
ATRA
Atara Biotherapeutics Inc
8 Jan 24
Cost Associated with Exit or Disposal Activities
8:11am
; the COVID-19 pandemic and the wars in Ukraine and the Middle East, which may significantly impact (i) our business, research, clinical development plans
8-K
EX-99.1
v81cg0d3377yuy
8 Jan 24
Cost Associated with Exit or Disposal Activities
8:11am
8-K
EX-99.1
mbeqjrbqy5t4rx
20 Dec 23
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
4:30pm
424B3
xir2fz9i
17 Nov 23
Prospectus supplement
4:31pm
8-K
EX-99.1
9qu 4ivzs
8 Nov 23
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 for Non-Active Progressive Multiple Sclerosis
9:16pm
8-K
EX-99.1
sllbehqr8eta8gmz0eq0
1 Nov 23
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
8:35am
8-K
EX-99.1
a5k5dkgm
19 Sep 23
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following
6:19pm
8-K
EX-99.1
8b9oswdzkxb1g26blb0
8 Aug 23
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
4:07pm
8-K
EX-99.1
ouxgl
8 May 23
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
4:06pm
CORRESP
e8kfcbkgwy zxts0
21 Apr 23
Correspondence with SEC
12:00am